NBIX
Neurocrine Biosciences, Inc.
Stock
$143.18+2.47 (+1.76%)Close Oct 2, 2026
- Selling, general and administrative, 2025
- $1.2B
- YoY, 2025
- +14.8%
- 5-year CAGR
- +21.7%
- 10-year CAGR
- +42.9%
Selling, general and administrative
Selling, general and administrative by fiscal year
| Period | SG&A | YoY |
|---|---|---|
| 2025 | $1.2B | +14.8% |
| 2024 | $1.0B | +13.5% |
| 2023 | $888M | +17.9% |
| 2022 | $753M | +29.0% |
| 2021 | $583M | +34.6% |
| 2020 | $433M | +22.4% |
| 2019 | $354M | +42.3% |
| 2018 | $249M | +46.5% |
| 2017 | $170M | +149.6% |
| 2016 | $68M | +109.6% |
| 2015 | $32M | — |